[{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ CMT Research Foundation","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ CMT Research Foundation"},{"orgOrder":0,"company":"ViaNautis Bio","sponsor":"SomaServe","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ViaNautis Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ViaNautis Bio \/ SomaServe","highestDevelopmentStatusID":"3","companyTruncated":"ViaNautis Bio \/ SomaServe"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intellia Therapeutics \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Intellia Therapeutics \/ ReCode Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Baylor College of Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Amber Bio","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Amber Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amber Bio \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Amber Bio \/ Playground Global"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Metagenomi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Pharmaceuticals \/ EdiGene"},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evozyne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evozyne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Deep Genomics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Oligonucleotide","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Deep Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deep Genomics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"3","companyTruncated":"Deep Genomics \/ SoftBank Vision Fund"},{"orgOrder":0,"company":"Vipergen","sponsor":"Casma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vipergen \/ Casma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Casma Therapeutics"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Genentech"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Obsidian Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Obsidian Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ring Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Ring Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neochromosome","sponsor":"University of Edinburgh","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neochromosome \/ University of Edinburgh","highestDevelopmentStatusID":"3","companyTruncated":"Neochromosome \/ University of Edinburgh"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"GondolaBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ GondolaBio","highestDevelopmentStatusID":"3","companyTruncated":"n-Lorem Foundation \/ GondolaBio"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Amazon Web Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ Amazon Web Services","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ Amazon Web Services"},{"orgOrder":0,"company":"Genetic Leap","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genetic Leap \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genetic Leap \/ Eli Lilly"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Lux Capital"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"iBRD9","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumi Scientific \/ X-Chem","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ X-Chem"},{"orgOrder":0,"company":"Rampart Bioscience","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rampart Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rampart Bioscience \/ OrbiMed Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Rampart Bioscience \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Protego Biopharma","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Unfolded protein response","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Protego Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protego Biopharma \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Protego Biopharma \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alltrna","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alltrna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alltrna \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Alltrna \/ Flagship Pioneering"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The collaboration aims to accelerate the discovery and development of CRISPR gene editing therapeutics through AI for treating cancer and genetic diseases.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Amazon Web Services

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The collaboration aims to discover novel antisense oligonucleotide (ASO) medicines for patients who are not currently served by available treatment options.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          December 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : GondolaBio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The funds will be used to advance ReviR's AI-driven drug discovery VoyageR platform, which will be leveraged to advance the clinical development of treatments for Huntington's disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 26, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Lapam Capital

                          Deal Size : Undisclosed

                          Deal Type : Series A Financing

                          blank

                          04

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The partnership with ReviR Therapeutics aligns perfectly with CMTRF's mission to accelerate the development of therapies for treating Charcot-Marie-Tooth disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 19, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : CMT Research Foundation

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The collaboration will leverage Genetic Leap's RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $409.0 million

                          May 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : Under the collaboration, Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 30, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The collaboration combines Intellia’s CRISPR platform and ReCode’s selective Organ Targeting lipid nanoparticle to correct cystic fibrosis-causing gene mutations.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 15, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : ReCode Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The collaboration aims to accelerate the development of new and more stable enzymes. Creating improved engineering processes for designer enzymes could lead to safer and more effective therapeutics, such as enzyme replacement therapy, for a broad range o...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : University of Edinburgh

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The disease models, ioSkeletal Myocytes DMD Exon 44 Deletion™ and ioSkeletal Myocytes DMD Exon 52 Deletion™, are designed to advance the discovery and development of treatments for Duchenne muscular dystrophy (DMD).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 07, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The proceeds from the round will fuel the rapid development of next generation of genetic nanomedicines using the polyNaut® platform, expand the scientific and management teams and establish industry-leading laboratory facilities.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 13, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : SomaServe

                          Deal Size : $25.0 million

                          Deal Type : Series A Financing

                          blank